Oxytocin Grindeks: Uses, Dosage & Side Effects
Oxytocin 8.3 microgram/ml – Solution for injection/infusion
Oxytocin Grindeks is a hospital-only prescription medicine containing the synthetic nonapeptide hormone oxytocin. Manufactured by JSC Grindeks in Riga, Latvia, it is used worldwide to induce or augment labor, manage miscarriage, prevent and treat postpartum hemorrhage (PPH), and promote uterine contraction during cesarean section. This evidence-based guide covers mechanism of action, approved indications, dosage protocols, drug interactions, side-effect profile, storage requirements, and the WHO's recommended place of oxytocin in obstetric care.
Quick Facts
Key Takeaways
- Oxytocin Grindeks contains synthetic oxytocin (8.3 micrograms/ml, approximately 5 IU/ml) and is used exclusively in hospitals under obstetric supervision to induce labor, augment weak contractions, manage miscarriage, control postpartum bleeding, and maintain uterine tone during cesarean section.
- Administration is always by a healthcare professional – either by titrated intravenous infusion or intramuscular injection – and the dose is continuously adjusted based on uterine activity and fetal heart rate monitoring.
- The World Health Organization (WHO) lists oxytocin as an Essential Medicine and recommends it as the first-line uterotonic for the prevention and treatment of postpartum hemorrhage, which remains the leading direct cause of maternal death worldwide.
- Oxytocin must not be administered within 6 hours of vaginal prostaglandin use, and caution is essential when combined with inhalational anesthetics, QT-prolonging drugs, or epidural vasoconstrictor agents.
- Store refrigerated at 2–8 °C; oxytocin is a heat-sensitive peptide and loss of potency is a recognized WHO concern, especially in warm climates. Once moved to room temperature (up to 25 °C), it must be used within 3 months and not returned to the fridge.
What Is Oxytocin Grindeks and What Is It Used For?
Quick Answer: Oxytocin Grindeks is a synthetic form of the naturally occurring hormone oxytocin, supplied as a clear solution for injection or infusion containing 8.3 micrograms/ml (approximately 5 International Units per ml). It is used in obstetric medicine to induce or strengthen labor, manage miscarriage, prevent and treat postpartum hemorrhage, and support uterine contraction during and after cesarean section. The product is manufactured by JSC Grindeks, one of the largest pharmaceutical manufacturers in the Baltic region.
Oxytocin is an endogenous peptide hormone produced by magnocellular neurons of the hypothalamus (in the paraventricular and supraoptic nuclei) and stored in, and released from, the posterior lobe of the pituitary gland. Structurally, it is a cyclic nonapeptide consisting of nine amino acids linked by a disulfide bridge between two cysteine residues. The synthetic oxytocin contained in Oxytocin Grindeks is chemically identical to the natural hormone and produces the same pharmacological effect, allowing clinicians to administer precise, titrated doses that mimic or replace physiological oxytocin release.
When administered, oxytocin binds to specific G-protein-coupled oxytocin receptors (OXTR) on the smooth muscle cells of the myometrium. This binding activates the phospholipase C pathway, increases intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG), and raises cytoplasmic calcium concentrations. The rise in calcium triggers rhythmic, coordinated uterine contractions that resemble the contractions of spontaneous labor. A key pharmacological principle is that myometrial sensitivity to oxytocin increases dramatically during pregnancy: receptor density is roughly 80-fold higher at term than in the non-pregnant uterus, which explains why oxytocin is effective only when the pregnancy is at term or near term.
Oxytocin Grindeks is manufactured in Riga, Latvia, by JSC Grindeks, a long-established Baltic pharmaceutical company that supplies oxytocin products to markets across Europe, the Commonwealth of Independent States, Africa, and Asia. Each 1 ml glass ampoule contains 8.3 micrograms of oxytocin, the standard EMA-approved strength that corresponds to approximately 5 International Units (IU) of biological activity. Ampoules are packed in cartons of 5 or 10 units, and the product is supplied with a detailed Summary of Product Characteristics (SmPC) for healthcare professionals.
Approved Indications
Oxytocin Grindeks is approved for the following clinical uses:
- Induction of labor: For medically indicated induction when continuation of pregnancy poses risk to mother or fetus – for example, post-term pregnancy (beyond 41–42 weeks), pre-eclampsia, gestational diabetes with poor control, intrauterine growth restriction, or prelabor rupture of membranes without spontaneous onset of contractions.
- Augmentation of labor: When spontaneous labor has started but contractions are insufficient to produce progressive cervical dilatation (often called uterine inertia, hypotonic dysfunction, or dysfunctional labor), carefully titrated oxytocin can strengthen and regulate contractions and shorten the active phase.
- Management of incomplete, inevitable, or missed miscarriage: To facilitate uterine evacuation, reduce blood loss, and promote return to normal uterine tone following first-trimester or early second-trimester pregnancy loss, including after surgical uterine evacuation or vacuum aspiration.
- Prevention and treatment of postpartum hemorrhage (PPH): Oxytocin is recommended by the World Health Organization as the first-line uterotonic agent for active management of the third stage of labor and is the reference drug in the treatment of atonic postpartum hemorrhage. PPH remains one of the leading direct causes of maternal mortality worldwide.
- Cesarean section: Administered after delivery of the infant to promote rapid and sustained uterine contraction, reduce blood loss during closure of the uterine incision, and minimize the risk of postoperative atony.
Oxytocin is included on the WHO Model List of Essential Medicines in the category of medicines for reproductive, maternal, newborn, and child health, reflecting its indispensable role in modern obstetric care. It is considered a core medicine in both high-income and low-resource healthcare systems and has been in clinical use since Vincent du Vigneaud's Nobel Prize-winning synthesis of the peptide in 1953.
Following intravenous administration, oxytocin has a rapid onset of uterine action within about one minute and a short plasma half-life of approximately 3–6 minutes. Steady-state plasma concentrations are reached within 40 minutes of starting an infusion. Oxytocin is eliminated primarily by degradation in the liver and kidneys, with additional inactivation by the placental enzyme oxytocinase (cystyl aminopeptidase). Only a small fraction is excreted unchanged in urine.
What Should You Know Before Receiving Oxytocin Grindeks?
Quick Answer: Oxytocin Grindeks must only be administered in a hospital setting under qualified obstetric supervision. Several absolute contraindications apply – including hypertonic uterine contractions, situations where vaginal delivery is not safe, and recent prostaglandin use – and careful caution is required in women with cardiovascular disease, renal impairment, or severe pre-eclampsia. Clinicians must monitor contraction pattern and fetal heart rate continuously throughout therapy.
Because oxytocin acts directly on the uterus and can profoundly alter the pattern of labor, a careful clinical assessment is required before it is prescribed. The prescriber considers the indication for induction or augmentation, gestational age, fetal presentation and wellbeing, cervical readiness (typically measured using the Bishop score), prior obstetric history, and any coexisting maternal medical conditions. Cardiotocographic (CTG) fetal heart rate monitoring and regular assessment of uterine contractions are mandatory during oxytocin infusion.
Contraindications
Oxytocin Grindeks must not be used in the following situations:
- Hypersensitivity: Known allergy to oxytocin or to any of the excipients listed in the product formulation (sodium acetate trihydrate, acetic acid, sodium chloride, sodium hydroxide, water for injections).
- Hypertonic uterine contractions: When the uterus is already contracting too strongly or too frequently, further oxytocin exposure can precipitate uterine rupture or fetal asphyxia.
- Cephalopelvic disproportion: When the fetal head is disproportionately large relative to the maternal pelvis and vaginal delivery cannot be safely achieved.
- Mechanical obstruction to delivery: Including abnormal fetal lie or presentation (such as transverse lie or brow presentation), placenta previa, vasa previa, and cord presentation or prolapse.
- Overdistended or at-risk uterus: Grand multiparity, polyhydramnios, or multiple pregnancy (twins or more) all carry a markedly increased risk of uterine rupture with oxytocin augmentation.
- Previous uterine surgery: Including classical or low-segment cesarean section, myomectomy that entered the uterine cavity, hysterotomy, or extensive cervical surgery. Use in this setting requires individualized specialist risk assessment.
- Fetal distress: When fetal distress is already present and delivery is not imminent, oxytocin may worsen the condition by further reducing placental perfusion.
- Severe toxemia of pregnancy: Severe pre-eclampsia and severe cardiovascular disorders are contraindications to prolonged oxytocin therapy.
- Recent vaginal prostaglandin use: Oxytocin Grindeks must not be started within 6 hours of vaginal prostaglandin administration because of the risk of synergistic uterine hyperstimulation.
Warnings and Precautions
Even when oxytocin is appropriately indicated, several clinical circumstances require particular caution:
- Cardiovascular disease: Women with hypertrophic cardiomyopathy, valvular heart disease, coronary artery disease, or previous myocardial infarction are more sensitive to the hemodynamic effects of oxytocin. Rapid intravenous bolus injection can precipitate acute, short-lived hypotension followed by reflex tachycardia, which may trigger myocardial ischemia in susceptible patients. Slow, titrated infusion is therefore preferred.
- Prolonged QT interval: Oxytocin has been associated with dose-related QT prolongation on ECG. Care should be taken in women with known long-QT syndrome, symptomatic QT prolongation, electrolyte disturbances (hypokalemia, hypomagnesemia), or concurrent use of other QT-prolonging drugs.
- Severe pre-eclampsia: Prolonged oxytocin use should be avoided in severe pre-eclamptic toxemia (hypertension, proteinuria, and edema after 24 weeks). The antidiuretic effect of oxytocin can worsen fluid overload in this group.
- Renal impairment: The antidiuretic activity of oxytocin (structurally related to vasopressin) may lead to water retention, dilutional hyponatremia, and seizures; dose reduction or longer dosing intervals may be needed.
- Advanced maternal age (>35 years): Myometrial compliance decreases with age, increasing the risk of hyperstimulation and uterine rupture, particularly in women with prior uterine scars.
- Large-volume fluid coadministration: Combining oxytocin with large volumes of electrolyte-free fluids (for example, 5% glucose) raises the risk of water intoxication and hyponatremia.
- Latex sensitivity: As with many parenteral products, caution is warranted in patients with known latex allergy because of rare reports of cross-reactive allergic reactions.
Oxytocin Grindeks must only be administered in a hospital setting with continuous cardiotocographic monitoring of uterine contractions and fetal heart rate. The infusion must be discontinued immediately if uterine hyperstimulation (too-frequent or too-strong contractions) or a non-reassuring fetal heart rate pattern occurs. Trained obstetric staff and resuscitation equipment must be immediately available throughout administration. Uterine rupture is a rare but potentially catastrophic complication, particularly in women with previous cesarean section or other uterine scars.
Pregnancy and Breastfeeding
Oxytocin Grindeks is specifically designed for use during pregnancy and the peripartum period. Its use for induction of labor must be strictly medically indicated and prescribed by a qualified obstetrician or midwife, with the expected benefits of timely delivery carefully weighed against the risks of continued pregnancy and the potential complications of oxytocin use. Elective induction in the absence of a clear medical indication is generally discouraged by international guidelines, including those of NICE and ACOG.
With respect to breastfeeding, only minute amounts of therapeutic oxytocin pass into breast milk, and no adverse effects on the nursing infant have been described. Oxytocin is in fact a key physiological driver of the milk let-down (ejection) reflex, released in pulses in response to suckling. The European Medicines Agency, the US Food and Drug Administration, and LactMed (the NLM lactation database) all consider oxytocin compatible with breastfeeding.
Fertility
There is no evidence that therapeutic use of oxytocin at recommended obstetric doses has any negative effect on subsequent female fertility. Oxytocin is not indicated in men, and the product has no approved use outside the peripartum period.
Driving and Operating Machinery
Oxytocin Grindeks is administered only in the inpatient setting, typically during labor or cesarean section, and the question of driving is rarely relevant. However, because labor, delivery, and oxytocin itself can cause drowsiness, headache, and transient cardiovascular changes, women should not drive or operate machinery until they have fully recovered from delivery and any residual effects of concomitant medications.
Sodium Content
Oxytocin Grindeks contains less than 1 mmol (23 mg) of sodium per ampoule, making it essentially "sodium-free" according to EMA labeling conventions. This is relevant for patients on strict sodium-restricted diets, although the total sodium load during a typical obstetric course is clinically negligible.
How Does Oxytocin Grindeks Interact with Other Drugs?
Quick Answer: Oxytocin Grindeks has clinically important interactions with prostaglandins (synergistic uterotonic effect), inhalational anesthetics (reduced uterine responsiveness and arrhythmias), QT-prolonging drugs (additive risk of torsades de pointes), and vasoconstrictor agents used with epidural anesthesia (potential hypertensive crisis). Concurrent use of oxytocin nasal spray is contraindicated, and large-volume fluid coadministration increases the risk of water intoxication.
Oxytocin is typically administered during a period when a woman may be receiving multiple other drugs – for example, epidural anesthesia, antibiotics, antiemetics, antihypertensives, or prostaglandins used for cervical ripening. Clinicians must therefore be aware of several pharmacodynamic and physiological interactions that can either intensify the desired uterotonic effect or produce harmful adverse outcomes.
Major Interactions
| Interacting Drug | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Prostaglandins (dinoprostone, misoprostol, gemeprost) | Synergistic uterotonic effect | Uterine hyperstimulation, tetanic contraction, possible uterine rupture, fetal hypoxia | Wait at least 6 hours after vaginal prostaglandins before starting oxytocin; use lowest effective dose |
| Inhalational anesthetics (cyclopropane, sevoflurane, desflurane, halothane, enflurane) | Reduced myometrial sensitivity; volatile anesthetic-related cardiovascular effects | Diminished uterine contractions, cardiac arrhythmia, enhanced hypotensive effect | Use lowest effective oxytocin dose; continuous ECG and blood-pressure monitoring; avoid high-dose volatile agents |
| QT-prolonging drugs (macrolide antibiotics, fluoroquinolones, antipsychotics, class III antiarrhythmics, ondansetron) | Additive QT prolongation | Increased risk of torsades de pointes and ventricular arrhythmia | ECG monitoring; correct electrolytes; avoid combination if safer alternatives exist |
| Oxytocin nasal spray | Additive systemic oxytocin exposure | Excessive uterotonic stimulation | Do not use simultaneously – this combination is contraindicated |
| Vasoconstrictor agents in epidural mixtures (e.g., epinephrine/adrenaline) | Potentiation of vasopressor effect | Risk of acute hypertension, cerebrovascular events | Continuous blood-pressure monitoring; careful selection of epidural composition |
Moderate and Minor Interactions
| Interacting Drug | Clinical Effect | Recommendation |
|---|---|---|
| Large-volume IV fluids (especially electrolyte-free) | Water intoxication due to oxytocin's antidiuretic effect; dilutional hyponatremia; cerebral edema | Restrict oral and IV fluid intake during prolonged infusion; monitor serum sodium; prefer electrolyte-containing solutions |
| Sympathomimetic vasopressors (phenylephrine, ephedrine, metaraminol) | Potentiated vasopressor effect; risk of severe hypertension | Use lowest effective vasopressor dose; monitor blood pressure closely |
| Ergot alkaloids (methylergometrine, ergometrine) | Additive uterotonic effect used therapeutically in severe PPH, but risk of hypertension and vasospasm | Used together in structured PPH protocols; monitor blood pressure; avoid in pre-eclampsia |
| Carbetocin (long-acting oxytocin analogue) | Redundant uterotonic effect | Do not administer concurrently in the same patient for the same indication |
During prolonged oxytocin infusion, patients are generally advised to limit oral fluid intake. This is because oxytocin shares structural homology with vasopressin (antidiuretic hormone) and exerts an antidiuretic effect. Combined with high-volume IV fluids – particularly electrolyte-free solutions such as 5% glucose – this can cause water retention, dilutional hyponatremia, and potentially life-threatening cerebral edema. Where possible, electrolyte-containing vehicles (such as 0.9% sodium chloride) are preferred, and serum sodium should be monitored during prolonged high-dose infusions.
What Is the Correct Dosage of Oxytocin Grindeks?
Quick Answer: Oxytocin Grindeks dosage is strictly individualized and always decided by a qualified obstetric team. For labor induction, it is given as a slow IV drip starting at 2–8 drops/min and titrated up in 20-minute intervals. For cesarean section and postpartum hemorrhage, 1 ml (8.3 mcg, approximately 5 IU) is typically given as an IV infusion over 5 minutes or by intramuscular injection. Rapid bolus injection must be avoided.
Because myometrial sensitivity to oxytocin varies widely between individuals and between clinical indications, dosing is always titrated to effect. The universal guiding principle is to use the lowest effective dose that produces adequate, regular uterine contractions, while continuously monitoring uterine activity and fetal well-being. All dilutions and infusion protocols below follow standard EMA and WHO-aligned recommendations.
Labor Induction and Augmentation
Intravenous Drip Infusion Protocol
Preparation: Dilute 0.2 ml of Oxytocin Grindeks 8.3 mcg/ml (equivalent to approximately 1 IU) in 100 ml of 0.9% sodium chloride solution, or 5% glucose for patients who should avoid sodium chloride. Invert the container several times to ensure thorough mixing.
Initial rate: 2–8 drops per minute (approximately 0.1–0.4 ml/min), equivalent to 1–4 milliunits per minute.
Titration: Increase the infusion rate at intervals of at least 20 minutes, guided by contraction frequency (target: 3–4 in 10 minutes), duration, intensity, and continuous fetal heart rate monitoring.
Maximum rate: Generally up to 40 drops per minute (approximately 2 ml/min or 20 mIU/min). Higher rates are rarely needed and are associated with increased risk of hyperstimulation.
Discontinuation: Stop immediately if uterine hyperstimulation (>5 contractions in 10 minutes or contractions lasting >2 minutes) or non-reassuring fetal heart rate occurs. If adequate contractions cannot be achieved after a cumulative dose of approximately 5 IU (1 ml of Oxytocin Grindeks), induction should be discontinued and alternative strategies considered.
Incomplete Miscarriage and Therapeutic Termination
Intravenous Infusion
Initial dose: 1.0 ml Oxytocin Grindeks 8.3 mcg/ml (approximately 5 IU) diluted in 0.9% sodium chloride, administered as an IV drip or preferably via a variable-rate infusion pump over 5 minutes.
During vacuum aspiration: 6 ml of Oxytocin Grindeks in 500 ml of 5% glucose (or 0.9% sodium chloride), infused intravenously once the cervix has been dilated to Hegar No. 8. Maximum infusion rate during the procedure is approximately 15 ml/min; after the procedure, reduce the rate to approximately 120 drops/min until the prescribed volume has been infused.
Prevention and Treatment of Postpartum Hemorrhage
Intramuscular or Intravenous
Prophylaxis (active management of the third stage of labor): 10 IU (2 ml Oxytocin Grindeks) intramuscularly immediately after delivery of the anterior shoulder or after delivery of the infant, in line with WHO 2018 recommendations.
Treatment of established PPH: 0.6–2.0 ml Oxytocin Grindeks 8.3 mcg/ml (equivalent to approximately 3–10 IU), given intramuscularly or as a slow IV infusion. A typical IV regimen is 1.0 ml diluted in 0.9% sodium chloride, administered by drip or infusion pump over 5 minutes, followed by a maintenance infusion if needed.
Refractory PPH: If bleeding does not respond, escalate to second-line uterotonics (ergometrine, carbetocin, misoprostol, carboprost) according to local PPH protocols, alongside resuscitation and surgical interventions.
Cesarean Section
Post-Delivery Infusion
Standard dose: 1.0 ml Oxytocin Grindeks 8.3 mcg/ml (approximately 5 IU) diluted in 0.9% sodium chloride, administered as an IV drip or preferably via a variable-rate infusion pump over 5 minutes, given immediately after delivery of the infant.
Maintenance infusion: A low-dose maintenance oxytocin infusion (for example, 10 IU in 500 ml at a rate titrated to uterine tone) is frequently continued postoperatively to reduce the risk of secondary atony.
Important: Rapid bolus injection must be avoided. High-dose IV bolus can cause acute profound hypotension, flushing, and reflex tachycardia, and has been associated with cardiac arrhythmia and myocardial ischemia, particularly in women with cardiovascular disease.
Missed Dose
Because Oxytocin Grindeks is only given in hospital by healthcare professionals, "missed doses" in the conventional sense do not occur. If a scheduled infusion is interrupted or delayed, the medical team will reassess the clinical situation, decide whether to resume the infusion, and adjust the rate according to current uterine activity and fetal status. Patients do not need to take any action themselves.
Special Populations
| Population | Recommendation |
|---|---|
| Hepatic impairment | Dose reduction or longer dosing intervals may be required; oxytocin is partly metabolized in the liver. |
| Renal impairment | Dose reduction or longer intervals may be required; monitor carefully for water retention and hyponatremia. |
| Elderly (≥65 years) | Not applicable – oxytocin has no approved use in elderly patients. |
| Children | Not applicable – oxytocin is not indicated in children. |
| Women with previous cesarean section | Use with caution at lower titrated doses; close monitoring for uterine rupture is essential. |
| Women with cardiovascular disease | Avoid rapid bolus injection; use slow infusion with continuous hemodynamic monitoring. |
Overdose
Oxytocin overdose produces uterine hyperstimulation with strong, prolonged, or tetanic contractions that can lead to uterine rupture, placental abruption, fetal bradycardia, fetal asphyxia, meconium-stained amniotic fluid, and, in rare cases, fetal or maternal death. Prolonged high-dose infusion in combination with large fluid volumes can also produce water intoxication with dilutional hyponatremia, hypoosmolality, seizures, and cerebral edema. Treatment is immediate discontinuation of the infusion, left lateral maternal positioning, oxygen therapy, IV crystalloid replacement as clinically indicated, and consideration of tocolytic therapy (e.g., terbutaline) for persistent hyperstimulation. Severe hyponatremia is managed with fluid restriction and, if seizures or severe neurological symptoms are present, cautious hypertonic saline under intensive care. Emergency cesarean delivery may be required if fetal compromise does not rapidly resolve.
What Are the Side Effects of Oxytocin Grindeks?
Quick Answer: Like all medicines, Oxytocin Grindeks can cause side effects, although not everyone gets them. Common effects include headache, nausea, vomiting, and heart-rate changes. Rare but serious effects include anaphylaxis, severe hypotension, uterine rupture, water intoxication with hyponatremia, and disseminated intravascular coagulation (DIC). Any unexpected or severe symptoms must be reported to the obstetric team immediately.
The adverse-effect profile of oxytocin is well characterized from more than six decades of global clinical use. Most side effects are dose-dependent and occur more often at higher infusion rates, with prolonged administration, or when oxytocin is combined with other uterotonics, inhalational anesthetics, or large fluid volumes. The following frequencies are aligned with the EMA-approved Summary of Product Characteristics for oxytocin-containing medicinal products and with the Cochrane and WHO systematic reviews.
Side Effect Frequency Overview
Common
May affect up to 1 in 10 patients
- Headache
- Decreased or increased heart rate (bradycardia/tachycardia)
- Nausea
- Vomiting
Uncommon
May affect up to 1 in 100 patients
- Cardiac arrhythmia (irregular heartbeat)
Rare
May affect up to 1 in 1,000 patients
- Skin rash
- Anaphylactic reactions (sudden rash, difficulty breathing, swelling, fainting)
- Laryngeal edema (swelling of the voice box)
- Anaphylactic shock (dangerously low blood pressure)
- Dyspnea (difficulty breathing)
Frequency Not Known
Reported from post-marketing surveillance
- Water intoxication (dilutional hyponatremia)
- Low blood sodium (hyponatremia)
- Chest pain due to myocardial ischemia
- QT prolongation on ECG
- Low blood pressure (hypotension)
- Acute pulmonary edema (fluid accumulation in the lungs)
- Disseminated intravascular coagulation (DIC)
- Uterine hypertonicity (excessively strong contractions)
- Uterine tetany (sustained contraction)
- Uterine rupture
- Flushing (sudden warmth sensation)
- Angioedema (swelling of face, tongue, or throat)
Effects on the Fetus and Newborn
Oxytocin can cross the placenta in small amounts, but its main impact on the fetus occurs indirectly through altered uterine contraction patterns that affect placental blood flow. Reported fetal and neonatal adverse effects include:
- Fetal bradycardia and variable decelerations: Slowing of the fetal heart rate, often the first sign of hyperstimulation-induced hypoxia and the trigger for discontinuing the infusion.
- Neonatal hyponatremia: Low blood sodium in the newborn, particularly when the mother has received large volumes of electrolyte-free fluids during prolonged induction.
- Fetal asphyxia and acidosis: Consequences of excessive or prolonged uterine contractions compromising placental perfusion.
- Neonatal jaundice: An association with higher-than-usual rates of neonatal jaundice has been reported, although mechanisms remain incompletely understood.
- Low Apgar scores or neonatal resuscitation: May occur more frequently after hyperstimulation-related fetal distress.
- Fetal death: Rare, most often associated with uterine rupture, placental abruption, or severe overdose.
Cardiovascular and Hemodynamic Effects
Rapid bolus IV administration of oxytocin can cause acute, short-lived hypotension, flushing, and reflex tachycardia. In women with pre-existing cardiovascular disease, these effects can precipitate chest pain, myocardial ischemia, arrhythmia, or, in rare cases, cardiac arrest. This is one of the main reasons why oxytocin is preferentially given as a slow titrated infusion rather than as a bolus, and why modern cesarean-section protocols often use a low-dose bolus followed by infusion.
Water Intoxication and Hyponatremia
Because oxytocin shares structural homology with vasopressin, it exerts a clinically relevant antidiuretic effect. In prolonged high-dose infusions – especially when combined with large volumes of electrolyte-free IV fluid – this can lead to hyponatremia with nausea, headache, confusion, seizures, and cerebral edema. Monitoring of fluid balance and serum sodium is essential during prolonged therapy.
All medicines used during labor and delivery, including oxytocin, have been described in rare cases in association with an increased risk of postpartum venous thromboembolism (deep vein thrombosis and pulmonary embolism). The overall contribution of oxytocin itself is probably small, but this background risk should be considered in the context of other postpartum risk factors such as immobility, cesarean section, obesity, and pre-eclampsia.
Reporting Side Effects
Patients, caregivers, and healthcare professionals are encouraged to report suspected adverse reactions through their national pharmacovigilance system. Reporting side effects helps provide more information on the safety of medicines – examples of reporting schemes include the UK Yellow Card Scheme, the US FDA MedWatch system, and the EMA EudraVigilance network. Serious or unexpected reactions should always be reported.
How Should Oxytocin Grindeks Be Stored?
Quick Answer: Store Oxytocin Grindeks in a refrigerator at 2–8 °C in the original packaging to protect from light. Do not freeze. Within its shelf life, it may be stored at room temperature (up to 25 °C) for a maximum of 3 months, but once removed from refrigeration it must not be returned to the fridge. After dilution, the infusion solution should be used within 24 hours.
Oxytocin is a labile peptide hormone whose potency declines over time when exposed to elevated temperatures, humidity, or light. The World Health Organization has drawn specific attention to heat-related degradation of oxytocin as a public-health concern, particularly in tropical and low-resource settings where maintaining an unbroken cold chain is challenging. Correct storage is therefore essential to ensure that each ampoule delivers the expected clinical effect in the critical moments of obstetric care.
Storage Conditions
- Primary storage: Refrigerate at 2–8 °C (36–46 °F) in the original carton to protect from light. Do not freeze.
- Room temperature storage: Within the shelf life printed on the ampoule, Oxytocin Grindeks may be stored at up to 25 °C (77 °F) for a maximum of 3 months. If not used during this period, it must be discarded.
- Once removed from refrigeration: The product must not be returned to the refrigerator. The date of removal should be noted on the carton.
- Before dilution: Each ampoule is for single use only. Inspect visually before use; the solution must be clear and colorless, without particles. Do not use if the ampoule is damaged or the solution has changed color.
- After dilution: The prepared infusion solution should be used within 24 hours when stored at up to 25 °C. Any unused solution should be discarded.
- Expiry date: Do not use after the expiration date printed on the packaging (marked "EXP"). The expiry date refers to the last day of the stated month.
- Keep out of sight and reach of children.
Disposal
Do not dispose of medicines via wastewater or household waste. Used ampoules and unused solution should be returned to a hospital pharmacy or local medicine collection point in accordance with national regulations. These measures help protect the environment and reduce the risk of accidental exposure.
What Does Oxytocin Grindeks Contain?
Quick Answer: Each 1 ml ampoule contains 8.3 micrograms of oxytocin as the active ingredient, equivalent to approximately 5 International Units (IU). The excipients are sodium acetate trihydrate, acetic acid, sodium chloride, sodium hydroxide (for pH adjustment), and water for injections. Oxytocin Grindeks is supplied as a clear, colorless sterile solution in transparent glass ampoules, typically in packs of 5 or 10.
Active Ingredient
The active substance is oxytocin. Each milliliter of solution contains 8.3 micrograms of synthetic oxytocin, equivalent to approximately 5 International Units (IU) of oxytocic activity. Oxytocin is a cyclic nonapeptide of sequence Cys–Tyr–Ile–Gln–Asn–Cys–Pro–Leu–Gly–NH2, with an intramolecular disulfide bridge between the two cysteine residues. The molecule has a molecular weight of approximately 1007 g/mol and differs from vasopressin (ADH) by just two amino acids, which explains the residual antidiuretic activity seen at higher therapeutic doses.
Excipients (Inactive Ingredients)
| Excipient | Function |
|---|---|
| Sodium acetate trihydrate | Buffering agent to stabilize pH |
| Acetic acid | pH adjustment |
| Sodium chloride | Tonicity adjustment (isotonicity) |
| Sodium hydroxide | pH adjustment |
| Water for injections | Solvent |
Pharmaceutical Form and Packaging
Oxytocin Grindeks is presented as a clear, colorless sterile solution in transparent 1 ml glass ampoules. Ampoules are packed in cartons of 5 or 10 units (depending on the country of distribution). The solution is intended for single use only; any unused portion must be discarded after opening. There is no antimicrobial preservative in the formulation, and the solution must therefore not be stored after the ampoule is broken.
Marketing Authorization Holder and Manufacturer
Oxytocin Grindeks is manufactured by JSC Grindeks at its facility in Riga, Latvia. JSC Grindeks is one of the largest pharmaceutical manufacturers in the Baltic region and produces oxytocin products distributed across Europe, the Commonwealth of Independent States, Africa, and Asia, often under local trade names such as Oxytocin Grindeks, Oxytocin Pilum, or national generic branding. The Summary of Product Characteristics, package leaflet, and labeling may vary slightly between countries; healthcare professionals should always consult the locally approved SmPC.
Frequently Asked Questions About Oxytocin Grindeks
Oxytocin Grindeks is used in hospital settings to induce or augment labor contractions when medically necessary, manage incomplete or inevitable miscarriage, prevent and treat postpartum hemorrhage (bleeding after delivery), and support uterine contraction during and after cesarean section. It contains the synthetic hormone oxytocin at a concentration of 8.3 micrograms per milliliter (approximately 5 IU/ml) and is administered exclusively by healthcare professionals via intravenous infusion or intramuscular injection.
Synthetic oxytocin in Oxytocin Grindeks is chemically identical to the oxytocin produced naturally by the body. The advantage of the synthetic form is that it can be given in precise, titrated doses and at a defined rate, which is impossible with endogenous hormone release. Natural oxytocin is released in pulses by the posterior pituitary gland and plays roles in labor, milk let-down during breastfeeding, and bonding; the synthetic version binds to exactly the same oxytocin receptors and produces the same uterotonic effect. It does not cross the blood–brain barrier in significant amounts at therapeutic doses.
Oxytocin Grindeks is classified under ATC code H01BB02 – "Posterior pituitary lobe hormones: oxytocin and analogues". Pharmacologically, it belongs to the group of uterotonic (oxytocic) agents, which are drugs that stimulate uterine contraction. Other medicines in closely related classes include carbetocin (a long-acting oxytocin analogue), ergometrine and methylergometrine (ergot alkaloids), and prostaglandins such as misoprostol, dinoprostone, and carboprost.
The most serious risks are uterine hyperstimulation (excessively strong or prolonged contractions), which can cause uterine rupture and major harm to both mother and baby; water intoxication with severe hyponatremia and cerebral edema, especially with prolonged high-dose infusion combined with large fluid volumes; and anaphylactic shock, which, though very rare, is a life-threatening allergic reaction. These risks are carefully managed through hospital-based administration, slow titration, continuous fetal and uterine monitoring, and immediate availability of emergency care.
No. Oxytocin Grindeks must only be administered in a hospital or equivalent clinical setting by qualified healthcare professionals. Administration requires continuous electronic monitoring of uterine contractions and fetal heart rate, access to emergency obstetric and resuscitation facilities, and the ability to perform an urgent cesarean delivery if needed. Self-administration would expose both mother and baby to extremely serious risks, including uterine rupture, severe fetal distress, and death, and is not permitted under any regulatory framework.
Yes. Only very small amounts of therapeutic oxytocin pass into breast milk, and no adverse effects on nursing infants have been documented. Oxytocin actually plays a crucial physiological role in breastfeeding by triggering the milk let-down reflex in response to suckling. Regulatory bodies including the European Medicines Agency and the NLM's LactMed database consider therapeutic oxytocin use fully compatible with breastfeeding. Your obstetric team or lactation consultant can discuss any specific concerns.
Oxytocin is a peptide hormone that degrades when exposed to elevated temperatures for prolonged periods. The WHO has specifically identified heat-related loss of oxytocin potency as a public-health concern in tropical and low-resource settings. Refrigerated storage at 2–8 °C maintains full potency throughout the product's shelf life, and the product may be kept at up to 25 °C for a maximum of 3 months if needed. Exposure to higher temperatures or extended room-temperature storage can reduce the drug's effectiveness, which is why careful cold-chain logistics are essential.
Oxytocin remains the first-line uterotonic recommended by the World Health Organization for both prevention and treatment of postpartum hemorrhage. Alternatives include carbetocin (a long-acting oxytocin analogue that does not require cold-chain storage in its heat-stable formulation), ergot alkaloids (ergometrine, methylergometrine), and prostaglandins (misoprostol, carboprost). A Cochrane network meta-analysis by Gallos and colleagues (2018) showed that the combination of ergometrine plus oxytocin and the prostaglandin misoprostol can be at least as effective as oxytocin alone for preventing PPH, but with more side effects. In most high-income settings, oxytocin remains preferred because of its rapid onset, predictable effect, and favorable safety profile at standard doses.
References & Sources
This article is based on the following peer-reviewed sources and international medical guidelines:
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: WHO.
- World Health Organization (WHO). WHO Recommendations: Uterotonics for the Prevention of Postpartum Haemorrhage (2018). Geneva: WHO.
- European Medicines Agency (EMA). Summary of Product Characteristics: Oxytocin-containing medicinal products. EMA/CHMP guidelines.
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 107: Induction of Labor (reaffirmed 2023). Obstetrics & Gynecology.
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 183: Postpartum Hemorrhage (2017, reaffirmed 2023). Obstetrics & Gynecology; 130(4):e168–e186.
- National Institute for Health and Care Excellence (NICE). Inducing Labour, NICE Guideline NG207 (2021, updated 2024). London: NICE.
- Gallos ID, Papadopoulou A, Man R, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews (2018), Issue 12. Art. No.: CD011689. DOI: 10.1002/14651858.CD011689.pub3.
- Dyer RA, van Dyk D, Dresner A. The use of uterotonic drugs during caesarean section. International Journal of Obstetric Anesthesia (2010); 19(3):313–319.
- Widmer M, Piaggio G, Nguyen TMH, et al. Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine (2018); 379(8):743–752.
- Torloni MR, Gomes Freitas C, Kartoglu UH, et al. Quality of oxytocin available in low- and middle-income countries: a systematic review. BJOG (2016); 123(13):2076–2086.
- British National Formulary (BNF). Oxytocin Monograph. London: BMJ Group & Pharmaceutical Press. Accessed December 2025.
- JSC Grindeks. Oxytocin Grindeks 8.3 microgram/ml Solution for Injection/Infusion – Summary of Product Characteristics. Riga: JSC Grindeks.
- WHO/UNICEF/UNFPA. Oxytocin in UN Commission on Life-Saving Commodities for Women and Children – Implementation Plan. New York: UNFPA.
Medical Editorial Team
This article has been written and reviewed by our medical editorial team, consisting of licensed physicians and clinical pharmacologists with specialist expertise in obstetrics, gynecology, and pharmacology.
Medical Review
Content reviewed by specialist physicians in obstetrics, gynecology, and clinical pharmacology in accordance with WHO, EMA, and ACOG guidelines.
Evidence Standard
All medical claims are supported by Level 1A evidence (systematic reviews and meta-analyses of randomized controlled trials) following the GRADE framework. No commercial funding or pharmaceutical sponsorship.